Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Quick facts
Marketed products
- Rubidium-82 · Cardiovascular
Rubidium-82 is a positron-emitting radioisotope that accumulates in myocardial tissue proportional to blood flow, allowing visualization of cardiac perfusion via PET imaging.
Phase 2 pipeline
- 18F-metaFluorobenzylguanidine · Oncology
18F-metaFluorobenzylguanidine is a radiopharmaceutical that selectively accumulates in neuroendocrine tumors, allowing for targeted imaging and therapy.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) portfolio CI brief
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) pipeline updates RSS
Frequently asked questions about Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
What are Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)'s marketed drugs?
Top marketed products include Rubidium-82.
Related
- Rubidium-82 · Cardiovascular
- Sector hub: All tracked pharma companies